Interferon-regulatory factor-1 boosts bevacizumab cardiotoxicity by the vascular endothelial growth factor A/14-3-3γ axis.
14-3-3γ
Bevacizumab
Interferon-regulatory factor-1
Myocardial injury
VEGFA
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
revised:
27
09
2023
received:
30
08
2022
accepted:
05
12
2023
medline:
18
1
2024
pubmed:
18
1
2024
entrez:
18
1
2024
Statut:
aheadofprint
Résumé
Myocardial injury is a significant cause of death. This study investigated the role and underlying mechanism of interferon-regulatory factor-1 (IRF1) in bevacizumab (BVZ)-induced cardiomyocyte injury. HL-1 cells and C57BL/6 mice receiving BVZ treatment were used to establish in vitro and in vivo models of myocardial injury. The relationship between VEGFA and 14-3-3γ was verified through co-immunoprecipitation and Glutathione S Transferase (GST) pull-down assay. Cell viability and apoptosis were analysed by MTT, propidium iodide (PI) staining and flow cytometry. The release of lactate dehydrogenase (LDH), cardiac troponins T (cTnT), and creatine kinase MB (CK-MB) was measured using the enzyme linked immunosorbent assay. The effects of knocking down IRF1 on BVZ-induced mice were analysed in vivo. IRF1 levels were increased in BVZ-treated HL-1 cells. BVZ treatment induced apoptosis, inhibited cell viability, and promoted the release of LDH, cTnT, and CK-MB. IRF1 silencing suppressed BVZ-induced myocardial injury, whereas IRF1 overexpression had the opposite effect. IRF1 regulated VEGFA expression by binding to its promoter, with the depletion of VEGFA or 14-3-3γ reversing the effects of IRF1 knockdown on the cell viability and apoptosis of BVZ-treated HL-1 cells. 14-3-3γ overexpression promoted cell proliferation, inhibited apoptosis, and reduced the release of LDH, cTnT, and CK-MB, thereby alleviating BVZ-induced HL-1 cell damage. In vivo, IRF1 silencing alleviated BVZ-induced cardiomyocyte injury by regulating the VEGFA/14-3-3γ axis. The IRF1-mediated VEGFA/14-3-3γ signalling pathway promotes BVZ-induced myocardial injury. Our study provides evidence for potentially new target genes for the treatment of myocardial injury.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82060679
Organisme : Jiangxi Provincial Health Department Project
ID : SKJP220212447
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Klein A, Loewenstein A. Therapeutic monoclonal antibodies and fragments: bevacizumab. Dev Ophthalmol 2016;55:232-245. doi:10.1159/000431199
Makhoul I, Todorova VK, Siegel ER, Erickson SW, Dhakal I, Raj VR, et al. Germline genetic variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA are associated with pathologic complete response to bevacizumab in breast cancer patients. PLoS ONE 2017;12:e0168550. doi:10.1371/journal.pone.0168550
Cui W, Li F, Yuan Q, Chen G, Chen C, Yu B. Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab. Oncotarget 2017;8:105472-105478. doi:10.18632/oncotarget.22295
Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precision Oncol 2018;2:13. doi:10.1038/s41698-018-0056-z
Li Y, Tian W, Yue D, Chen C, Li C, Zhang Z, et al. Bevacizumab-induced mitochondrial dysfunction, endoplasmic reticulum stress, and ERK inactivation contribute to cardiotoxicity. Oxid Med Cell Longev 2021;2021:5548130. doi:10.1155/2021/5548130
Yıldırım E, Yıldırım N, Cengiz M, Yazıcı GN, Coskun R, Suleyman B, et al. Protective effect of adenosine triphosphate and benidipine separately or together against cardiotoxicity caused by bevacizumab. Biotech Histochem 2023;98:193-200. doi:10.1080/10520295.2022.2153385
Oncel CR, Ovey IS. The role of selenium in bevacizumab induced cardiotoxicity. Bratisl Lek Listy 2019;120:131-138. doi:10.4149/BLL_2019_021
Chen XY, Huang WL, Peng XP, Lv YN, Li JH, Xiong JP. miR-140-5p mediates bevacizumab-induced cytotoxicity to cardiomyocytes by targeting the VEGFA/14-3-3γ signal pathway. Toxicol Res 2019;8:875-884. doi:10.1039/c9tx00100j
Fei L, Zhang J, Niu H, Yuan C, Ma X. Effects of Rosuvastatin and MiR-126 on myocardial injury induced by acute myocardial infarction in rats: Role of vascular endothelial growth factor a (VEGF-A). Med Sci Monit 2016;22:2324-2334. doi:10.12659/MSM.896983
Zenke K, Muroi M, Tanamoto KI. IRF1 supports DNA binding of STAT1 by promoting its phosphorylation. Immunol Cell Biol 2018;96:1095-1103. doi:10.1111/imcb.12185
Zhang XJ, Jiang DS, Li H. The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases. Br J Pharmacol 2015;172:5457-5476. doi:10.1111/bph.12881
Jiang W, Chen G, Pu J. The transcription factor interferon regulatory factor-1 is an endogenous mediator of myocardial ischemia reperfusion injury. Cell Biol Int 2022;46:63-72. doi:10.1002/cbin.11713
Qiao A, Zhao Z, Zhang H, Sun Z, Cui X. Gene expression profiling reveals genes and transcription factors associated with dilated and ischemic cardiomyopathies. Pathol Res Pract 2017;213:548-557. doi:10.1016/j.prp.2016.12.017
Yan Y, Zheng L, du Q, Yazdani H, Dong K, Guo Y, et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett 2021;506:95-106. doi:10.1016/j.canlet.2021.03.002
Ma Z, Li K, Chen P, Pan Q, Li X, Zhao G. MiR-134, mediated by IRF1, suppresses tumorigenesis and progression by targeting VEGFA and MYCN in osteosarcoma. Anticancer Agents Med Chem 2020;20:1197-1208. doi:10.2174/1871520620666200402074752
Obsilova V, Obsil T. The 14-3-3 proteins as important allosteric regulators of protein kinases. Int J Mol Sci 2020;21:8824. doi:10.3390/ijms21228824
Fan X, Cui L, Zeng Y, Song W, Gaur U, Yang M. 14-3-3 proteins are on the crossroads of cancer, aging, and age-related neurodegenerative disease. Int J Mol Sci 2019;20:3518. doi:10.3390/ijms20143518
He H, Luo Y, Qiao Y, Zhang Z, Yin D, Yao J, et al. Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative stress and preventing mitochondrial dysfunction mediated by 14-3-3γ. Food Funct 2018;9:4404-4418. doi:10.1039/C8FO00466H
Liang J, Piao Y, Henry V, Tiao N, de Groot JF. Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. Oncotarget 2015;6:31479-31492. doi:10.18632/oncotarget.5491
Miao JX, Gao S, Fan L, Cao F. Progress in prevention and treatment of myocardial injury induced by cancer therapy. Chin Med J (Engl) 2019;132:2724-2728. doi:10.1097/CM9.0000000000000498
Stein-Merlob AF, Rothberg MV, Ribas A, Yang EH. Cardiotoxicities of novel cancer immunotherapies. Heart (British Cardiac Society) 2021;107:1694-1703. doi:10.1136/heartjnl-2020-318083
Zhang SD, McCrudden CM, Meng C, Lin Y, Kwok HF. The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. Onco Targets Ther 2015;8:835-843. doi:10.2147/OTT.S80518
Jia M, Guo Y, Zhu D, Zhang N, Li L, Jiang J, et al. Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-κB pathway. Biochim Biophys Acta Mol Basis Dis 2018;1864:1622-1633. doi:10.1016/j.bbadis.2018.01.021
Katoh M, Takeda N, Arimoto T, Abe H, Oda K, Osuga Y, et al. Bevacizumab-related microvascular angina and its management with nicorandil. Int Heart J 2017;58:803-805. doi:10.1536/ihj.16-537
Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J. Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol 2020;30:66-71. doi:10.1177/1120672118823128
Yoshimoto T, Yoshikawa K, Higashijima J, Miyatani T, Tokunaga T, Nishi M, et al. Bevacizumab-associated intestinal perforation and perioperative complications in patients receiving bevacizumab. Ann Gastroenterol Surg 2020;4:151-155. doi:10.1002/ags3.12312
Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P, et al. 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol 2017;174:3713-3726. doi:10.1111/bph.13725
Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 2015;309:H1453-H1467. doi:10.1152/ajpheart.00554.2015
Hashimoto N, Kitano D, Tamaki T, Koyama Y, Yamada A, Hatakeyama K, et al. Autopsy and cardiac magnetic resonance image case of bevacizumab-related cardiomyopathy. J Cardiovasc Dev Dis 2022;9:208. doi:10.3390/jcdd9070208
Bhadana R, Rani V. A patent review on cardiotoxicity of Anticancerous drugs. Cardiovasc Hematol Agents Med Chem 2023;22:28-39. doi:10.2174/1871525721666230120155734
Qin S, Li J, Bai Y, Shu Y, Li W, Yin X, et al. Efficacy, safety, and immunogenicity of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: Results of a randomized, double-blind phase III study. BioDrugs 2021;35:445-458. doi:10.1007/s40259-021-00484-9
Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, et al. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab. Regul Toxicol Pharmacol 2018;95:236-243. doi:10.1016/j.yrtph.2018.03.020
Liu W, Zhang J, Yao X, Jiang C, Ni P, Cheng L, et al. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor a/vascular endothelial growth factor receptor 2-specificity protein 1 pathway. Cancer Sci 2018;109:3294-3304. doi:10.1111/cas.13779
Sabet NS, Atashbar S, Khanlou EM, Kahrizi F, Salimi A. Curcumin attenuates bevacizumab-induced toxicity via suppressing oxidative stress and preventing mitochondrial dysfunction in heart mitochondria. Naunyn Schmiedebergs Arch Pharmacol 2020;393:1447-1457. doi:10.1007/s00210-020-01853-x
Feng H, Zhang YB, Gui JF, Lemon SM, Yamane D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog 2021;17:e1009220. doi:10.1371/journal.ppat.1009220
Alsamman K, El-Masry OS. Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 2018;38: doi:10.1042/BSR20171672
Yan Y, Zheng L, du Q, Cui X, Dong K, Guo Y, et al. Interferon regulatory factor 1 (IRF-1) downregulates checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in hepatocellular carcinoma (HCC) cells. Br J Cancer 2021;125:101-111. doi:10.1038/s41416-021-01337-6
Yang Y, Yang W, Huo W, Huo P, Yang H. Identification of biomarkers for ischemic cardiomyopathy based on microarray data analysis. Cardiol J 2017;24:305-313. doi:10.5603/CJ.a2017.0005
Guo M, Yan R, Ji Q, Yao H, Sun M, Duan L, et al. IFN regulatory Factor-1 induced macrophage pyroptosis by modulating m6A modification of circ_0029589 in patients with acute coronary syndrome. Int Immunopharmacol 2020;86:106800. doi:10.1016/j.intimp.2020.106800
Jiao Y, Li Y, Zhang J, Zhang S, Zha Y, Wang J. RRM2 alleviates doxorubicin-induced cardiotoxicity through the AKT/mTOR signaling pathway. Biomolecules 2022;12:299. doi:10.3390/biom12020299
Lu J, Zhang C, Wang W, Xu W, Chen W, Tao L, et al. Exposure to environmental concentrations of glyphosate induces cardiotoxicity through cellular senescence and reduced cell proliferation capacity. Ecotoxicol Environ Saf 2023;261:115112. doi:10.1016/j.ecoenv.2023.115112
Jiang DS, Li L, Huang L, Gong J, Xia H, Liu X, et al. Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension (Dallas, Tex : 1979) 2014;64:77-86. doi:10.1161/HYPERTENSIONAHA.114.03229
Huang Y, Wang S, Zhou J, Liu Y, du C, Yang K, et al. IRF1-mediated downregulation of PGC1α contributes to cardiorenal syndrome type 4. Nat Commun 2020;11:4664. doi:10.1038/s41467-020-18519-0
Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med 2020;15:199-210. doi:10.1007/s11739-019-02253-7
Chen S, Feng X, Chen X, Zhuang Z, Xiao J, Fu H, et al. 14-3-3γ, a novel regulator of the large-conductance ca(2+)-activated K(+) channel. Am J Physiol Renal Physiol 2020;319:F52-f62. doi:10.1152/ajprenal.00584.2019
Huang B, You J, Qiao Y, Wu Z, Liu D, Yin D, et al. Tetramethylpyrazine attenuates lipopolysaccharide-induced cardiomyocyte injury via improving mitochondrial function mediated by 14-3-3γ. Eur J Pharmacol 2018;832:67-74. doi:10.1016/j.ejphar.2018.05.019
Chen X, Peng X, Luo Y, You J, Yin D, Xu Q, et al. Quercetin protects cardiomyocytes against doxorubicin-induced toxicity by suppressing oxidative stress and improving mitochondrial function via 14-3-3γ. Toxicol Mech Methods 2019;29:344-354. doi:10.1080/15376516.2018.1564948